Doog, understand when I say Regabatin is dead, I mean as far as any valuation factor for next 7 years as outlined. Then because of generics coming on market in 2018 AND having to compete against another ER product which will have been established I feel the value is now decreased and we wont be able to properly value it until sometime in the future. so for any current investor, unless they were planning on holding long term beyond those 7 years, I see it as as dead issue for any price effect to help us.
as for the all the activity on the patent side, it is what he does. Wim outlined it the best. he is acting like he is a researcher at a University using grant money and the end product is another patent.
We already read where he has initiated another companion to the Podras patent! for god sake it hasn't even been proven in humans yet and he s going after another patent for it!
the only thing these patents do will help him win his cases in court o prove he used his own technology. but he is forgetting they need to be put to use. it does no good without a partner which he has failed to secure in the last 2 years, which they know they need. so he continues to waste funds bolstering his patent as the drug sits idle.
as for keeping us in the dark, you are correct. if it wasnt for me just happening to question the year end last year when were we even told they filed another ANDA? they have yet to even notify us about that one!
